Aduro Announces Presentation on Small-Molecule Immunotherapy Program at SITC Conference
Aduro BioTech Inc.
Posted on: 05 Nov 13
Aduro BioTech Inc. announces an oral presentation entitled “Modified STING-Activating Cyclic Dinucleotide Derivatives Significantly Enhance the Anti-Tumor Activity of Therapeutic Vaccines” at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor Maryland. Thomas W. Dubensky Jr. chief scientific officer of Aduro will be presenting at 10:45 am on Saturday November 9 2013.
“We are developing small-molecule clinical candidates that activate STING (STimulator of INterferon Genes) a central mediator of the innate immune response” said Stephen Isaacs chairman and chief executive officer at Aduro “and we’re excited to present our recent progress.”
About Aduro BioTech Inc.
Aduro BioTech Inc. is a clinical-stage immunotherapy company located in Berkeley California. In addition to small molecules that activate STING the company is developing immunotherapies based on live-attenuated Listeriamonocytogenes and on irradiated GM-CSF-expressing tumor cells. Aduro has completed enrollment in a randomized controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. The company’s pipeline includes programs in glioblastoma non-small-cell lung cancer ovarian cancer prostate cancer and malaria.
Business Wire
http://www.businesswire.com/
Last updated on: 05/11/2013
0 comments:
Post a Comment